References

The diagnosis and treatment of prostate cancer: a review

10.1001/jama.2017.7248 · 2017 · External reference

Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3

10.1200/jco.2008.20.4669 · 2009 · External reference

Risk of pathologic upgrading or locally advanced disease in early prostate cancer patients based on biopsy Gleason score and PSA: a population-based study of modern patients

10.1016/j.ijrobp.2015.01.051 · 2015 · External reference

Low-risk prostate cancer and tumor upgrading in the surgical specimen: analysis of clinical factors predicting tumor upgrading in a contemporary series of patients who were evaluated according to the modified Gleason score grading system

10.1159/000447164 · 2017 · External reference

Heterogeneity in D'Amico classification-based low-risk prostate cancer: differences in upgrading and upstaging according to active surveillance eligibility

10.1016/j.urolonc.2015.04.004 · 2015 · External reference

The metabolic landscape of prostate cancer

10.1016/j.euo.2018.06.010 · 2019 · External reference

Metabolomics biomarkers of prostate cancer: a systematic review

10.3390/diagnostics9010021 · 2019 · External reference

Metabolomic biomarkers of prostate cancer: prediction, diagnosis, progression, prognosis, and recurrence

10.1158/1055-9965.epi-15-1223 · 2016 · External reference

Advances and perspectives in prostate cancer biomarker discovery in the last 5 years through tissue and urine metabolomics

10.3390/metabo11030181 · 2021 · External reference

Metabolic profiling in formalin-fixed and paraffin-embedded prostate cancer tissues

10.1158/1541-7786.mcr-16-0262 · 2017 · External reference

Metabolomics of prostate cancer Gleason score in tumor tissue and serum

10.1158/1541-7786.mcr-20-0548 · 2021 · External reference

The potential role of fatty acids in prostate cancer determined by GC-MS analysis of formalin-fixed paraffin-embedded tissue samples

10.1016/j.jpba.2021.113907 · 2021 · External reference

Unresolved reference

External reference

Assessment of small metabolites in plasma, formalin-fixed paraffin-embedded tumor and normal tissue in men with prostate cancer

2018 · External reference

Metabolomic signatures of aggressive prostate cancer

10.1002/pros.22704 · 2013 · External reference

A new rule-based algorithm for identifying metabolic markers in prostate cancer using tandem mass spectrometry

10.1093/bioinformatics/btn506 · 2008 · External reference

Preoperative metabolic signatures of prostate cancer recurrence following radical prostatectomy

10.1021/acs.jproteome.8b00926 · 2019 · External reference

Pre-diagnostic metabolite concentrations and prostate cancer risk in 1077 cases and 1077 matched controls in the European Prospective Investigation into Cancer and Nutrition

10.1186/s12916-017-0885-6 · 2017 · External reference

Plasma free amino acid profiling of five types of cancer patients and its application for early detection

10.1371/journal.pone.0024143 · 2011 · External reference

Leucine-rich repeat-containing G protein-coupled receptor 4 (Lgr4) is necessary for prostate cancer metastasis via epithelial-mesenchymal transition

10.1074/jbc.m116.771931 · 2017 · External reference

Prostate cancer cells in different androgen receptor status employ different leucine transporters

10.1002/pros.23263 · 2017 · External reference

EGF-activated PI3K/Akt signalling coordinates leucine uptake by regulating LAT3 expression in prostate cancer

10.1186/s12964-019-0400-0 · 2019 · External reference

Prospective serum metabolomic profile of prostate cancer by size and extent of primary tumor

10.18632/oncotarget.16775 · 2017 · External reference

Metabolomic analysis of prostate cancer risk in a prospective cohort: the alpha-tocolpherol, beta-carotene cancer prevention (ATBC) study

10.1002/ijc.29576 · 2015 · External reference

Plasma metabolomic profiles and risk of advanced and fatal prostate cancer

10.1016/j.euo.2019.07.005 · 2021 · External reference

limma powers differential expression analyses for RNA-sequencing and microarray studies

10.1093/nar/gkv007 · 2015 · External reference

Serine and glycine metabolism in cancer

10.1016/j.tibs.2014.02.004 · 2014 · External reference

Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells

10.1038/nature11743 · 2013 · External reference

The importance of plasma arginine level and its downstream metabolites in diagnosing prostate cancer

10.1007/s11255-019-02261-8 · 2019 · External reference

Cellular metabolism and disease: what do metabolic outliers teach us

10.1016/j.cell.2012.02.032 · 2012 · External reference

Human prostate cancer is characterized by an increase in urea cycle metabolites

10.3390/cancers12071814 · 2020 · External reference

The context-specific roles of urea cycle enzymes in tumorigenesis

10.1016/j.molcel.2021.08.005 · 2021 · External reference

Reprogramming of serine, glycine and one-carbon metabolism in cancer

10.1016/j.bbadis.2020.165841 · 2020 · External reference

Glycine consumption and mitochondrial serine hydroxymethyltransferase in cancer cells: the heme connection

10.1016/j.mehy.2013.02.008 · 2013 · External reference

Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation

10.1126/science.1218595 · 2012 · External reference

Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells

10.1038/cddis.2013.393 · 2013 · External reference

Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status

10.1186/s12885-020-06908-z · 2020 · External reference

Seminal plasma metabolomics reveals lysine and serine dysregulation as unique features distinguishing between prostate cancer tumors of Gleason grades 6 and 7

10.1002/pros.24145 · 2021 · External reference

Post-treatment urinary sarcosine as a predictor of recurrent relapses in patients with prostate cancer

10.1002/cam4.1767 · 2018 · External reference

Prospective serum metabolomic profiling of lethal prostate cancer

10.1002/ijc.32218 · 2019 · External reference

Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial

10.1038/bjc.2016.305 · 2016 · External reference

The role of sarcosine metabolism in prostate cancer progression

10.1593/neo.13314 · 2013 · External reference

Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

10.1093/carcin/bgt176 · 2013 · External reference

Metabolomics-derived prostate cancer biomarkers: fact or fiction

10.1021/pr5011108 · 2015 · External reference

Integrated RNA and metabolite profiling of urine liquid biopsies for prostate cancer biomarker discovery

10.1038/s41598-020-60616-z · 2020 · External reference

Subpathway-GM: identification of metabolic subpathways via joint power of interesting genes and metabolites and their topologies within pathways

10.1093/nar/gkt161 · 2013 · External reference

Rapid diagnosis of prostate cancer disease progression using paper spray ionization mass spectrometry

10.1021/acs.analchem.1c00943 · 2021 · External reference

Plasma metabolomic profile in prostatic intraepithelial neoplasia and prostate cancer and associations with the prostate-specific antigen and the Gleason score

10.1007/s11306-020-01694-y · 2020 · External reference

Integration of tissue metabolomics, transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate cancer

10.18632/oncotarget.6370 · 2016 · External reference

1-stearoylglycerol is associated with risk of prostate cancer: results from serum metabolomic profiling

10.1158/1538-7445.am2014-5068 · 2014 · External reference

Preclinical evaluation of (11)C-sarcosine as a substrate of proton-coupled amino acid transporters and first human application in prostate cancer

10.2967/jnumed.116.173179 · 2017 · External reference

Rapid prostate cancer noninvasive biomarker screening using segmented flow mass spectrometry-based untargeted metabolomics

10.1021/acs.jproteome.0c00006 · 2020 · External reference

A landscape of metabolic variation across tumor types

10.1016/j.cels.2017.12.014 · 2018 · External reference

Seminal plasma enables selection and monitoring of active surveillance candidates using nuclear magnetic resonance-based metabolomics: a preliminary investigation

10.1016/j.prnil.2017.03.005 · 2017 · External reference

Metabolomics and transcriptomics profiles reveal the dysregulation of the tricarboxylic acid cycle and related mechanisms in prostate cancer

10.1002/ijc.31313 · 2018 · External reference

Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression

10.1038/nature07762 · 2009 · External reference

Serum methionine metabolites are risk factors for metastatic prostate cancer progression

10.1371/journal.pone.0022486 · 2011 · External reference

Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol

10.1371/journal.pone.0014175 · 2010 · External reference

The urinary sarcosine/creatinine ratio is a potential diagnostic and prognostic marker in prostate cancer

10.12659/msm.909949 · 2018 · External reference

NMR-based metabolomics analysis identifies discriminatory metabolic disturbances in tissue and biofluid samples for progressive prostate cancer

10.1016/j.cca.2019.10.046 · 2020 · External reference

Distinct metabolic signatures of hormone-sensitive and castration-resistant prostate cancer revealed by a (1)H NMR-based metabolomics of biopsy tissue

10.1021/acs.jproteome.0c00282 · 2020 · External reference

Metabolomic profiling from formalin-fixed, paraffin-embedded tumor tissue using targeted LC/MS/MS: application in sarcoma

10.1371/journal.pone.0025357 · 2011 · External reference

A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue

10.1038/nprot.2012.024 · 2012 · External reference

The effect of sample age on the metabolic information extracted from formalin-fixed and paraffin embedded tissue samples using desorption electrospray ionization mass spectrometry imaging

10.1016/j.jmsacl.2021.10.004 · 2021 · External reference

UPLC‑MS/MS‑based metabolomic characterization and comparison of pancreatic adenocarcinoma tissues using formalin‑fixed, paraffin‑embedded and optimal cutting temperature6‑embedded materials

10.3892/ijo.2019.4898 · 2019 · External reference

Metabolic profiling of formalin-fixed paraffin-embedded tissues discriminates normal colon from colorectal cancer

10.1158/1541-7786.mcr-19-1091 · 2020 · External reference

High-resolution MALDI-FT-ICR MS imaging for the analysis of metabolites from formalin-fixed, paraffin-embedded clinical tissue samples

10.1002/path.4560 · 2015 · External reference

High-mass-resolution MALDI mass spectrometry imaging of metabolites from formalin-fixed paraffin-embedded tissue

10.1038/nprot.2016.081 · 2016 · External reference

Lipidomic analysis of archival pathology specimens identifies altered lipid signatures in ovarian clear cell carcinoma

10.3390/metabo11090597 · 2021 · External reference

A new technological approach in diagnostic pathology: mass spectrometry imaging-based metabolomics for biomarker detection in urachal cancer

10.1038/s41374-021-00612-7 · 2021 · External reference

Detection of metabolites discriminating subtypes of thyroid cancer: molecular profiling of FFPE samples using the GC/MS approach

10.1016/j.mce.2015.09.021 · 2015 · External reference